AYTU BIOPHARMA, INC Business Acquisition, Pro Forma Revenue
AYTU BIOPHARMA, INC (AYTU) reported Business Acquisition, Pro Forma Revenue of $69.22 million for the 9-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2022-05-16
- AYTU BIOPHARMA, INC business acquisition, pro forma revenue for the quarter ending 2022-03-31 was $24.20M, a 8.75% increase year-over-year.
- AYTU BIOPHARMA, INC business acquisition, pro forma revenue for the quarter ending 2021-12-31 was $23.13M, a 11.99% decline year-over-year.
- AYTU BIOPHARMA, INC business acquisition, pro forma revenue for the quarter ending 2021-09-30 was $21.90M, a 15.96% decline year-over-year.
- AYTU BIOPHARMA, INC business acquisition, pro forma revenue for the quarter ending 2021-06-30 was $23.48M, a 62.85% increase year-over-year.
- AYTU BIOPHARMA, INC business acquisition, pro forma revenue for fiscal 2021 was $98.06M, a 0.52% increase from fiscal 2020.
- AYTU BIOPHARMA, INC business acquisition, pro forma revenue for fiscal 2020 was $97.56M, a 149.87% increase from fiscal 2019.
- AYTU BIOPHARMA, INC business acquisition, pro forma revenue for fiscal 2019 was $39.04M.
- AYTU BIOPHARMA, INC business acquisition, pro forma revenue for fiscal 2015 was $1.37M, a 21.03% decline from fiscal 2014.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 3 month as first filed | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 9 month as first filed | Business Acquisition, Pro Forma Revenue 12 month | Business Acquisition, Pro Forma Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2022-03-31 | $24.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | $47.32M derived: sum of 2 quarters · filed 2022-05-16 | $69.22M 10-Q · filed 2022-05-16 | $92.70M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2021-12-31 | $23.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $45.02M 10-Q · filed 2022-02-14 | $68.50M derived: sum of 3 quarters · filed 2022-02-14 | $90.75M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2021-09-30 | $21.90M 10-Q · filed 2021-11-15 | $45.38M derived: sum of 2 quarters · filed 2021-11-15 | $67.63M derived: sum of 3 quarters · filed 2022-05-16 | $93.91M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2021-06-30 | $23.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $45.73M derived: sum of 2 quarters · filed 2022-05-16 | $72.01M derived: sum of 3 quarters · filed 2022-05-16 | $98.06M 10-K · filed 2021-09-28 | |||
| 2021-03-31 | $22.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | $48.53M derived: sum of 2 quarters · filed 2022-05-16 | $74.58M 10-Q · filed 2022-05-16 | $89.00M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $26.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $52.33M 10-Q · filed 2022-02-14 | $66.75M derived: sum of 3 quarters · filed 2022-02-14 | $91.58M derived: sum of 4 quarters · filed 2022-02-14 | |||
| 2020-09-30 | $26.05M 10-Q · filed 2021-11-15 | $40.47M derived: sum of 2 quarters · filed 2021-11-15 | $65.30M derived: sum of 3 quarters · filed 2021-11-15 | $74.23M derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $14.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $39.24M derived: sum of 2 quarters · filed 2021-09-28 | $48.17M derived: sum of 3 quarters · filed 2021-09-28 | $97.56M 10-K · filed 2021-09-28 | $35.56M 10-K · filed 2020-10-06 | ||
| 2020-03-31 | $24.82M 10-Q · filed 2021-05-17 | $10.33M 10-Q · filed 2020-05-15 | $33.75M derived: sum of 2 quarters · filed 2021-05-17 | $83.14M 10-Q · filed 2021-05-17 | $34.28M 10-Q · filed 2020-05-15 | $46.49M derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-12-31 | $8.93M 10-Q · filed 2021-02-11 | $20.54M 10-Q · filed 2021-02-11 | $21.66M derived: sum of 3 quarters · filed 2021-02-11 | $32.24M derived: sum of 4 quarters · filed 2021-02-11 | |||
| 2019-09-30 | $10.61M 10-Q · filed 2020-11-12 | $12.73M derived: sum of 2 quarters · filed 2020-11-12 | $23.31M derived: sum of 3 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $12.70M derived: sum of 2 quarters · filed 2020-10-06 | $39.04M 10-K · filed 2020-10-06 | ||||
| 2019-03-31 | $10.58M 10-Q · filed 2020-05-15 | $36.92M 10-Q · filed 2020-05-15 | |||||
| 2015-06-30 | $1.37M 10-K · filed 2015-09-28 | ||||||
| 2014-06-30 | $1.74M 10-K · filed 2015-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |